Transcatheter Aortic Valve Replacement

Transcatheter Aortic Valve Replacement in Paradoxical Low-Flow, Low-Gradient Aortic Stenosis: Insights from the REBOOT-PARADOX Trial

By MedXY 09/02/2026

The REBOOT-PARADOX trial evaluated TAVR plus medical therapy versus medical treatment alone in symptomatic paradoxical low-flow, low-gradient aortic stenosis, showing no definitive mortality benefit but supporting personalized care with timely valve replacement.

Cardiology news

Decade-Long Outcomes of SAPIEN 3 TAVR vs. Surgery in Intermediate-Risk Aortic Stenosis Patients

By MedXY 06/20/2026

This analysis reveals comparable 10-year mortality, valve durability, and hemodynamics between SAPIEN 3 transcatheter and surgical aortic valve replacement in intermediate-risk patients, underscoring TAVR's durable benefit.

Cardiology news

Self-Expanding Valves Outperform Balloon-Expandable Systems in Hemodynamics for Small Valve-in-Valve TAVR: 3-Year LYTEN Trial Results

By MedXY 03/03/2026

The 3-year results of the LYTEN trial demonstrate that self-expanding valves provide significantly better hemodynamic performance than balloon-expandable valves for failed small surgical bioprostheses, although clinical outcomes like mortality and stroke remain comparable between the two systems.

Cardiology news Specialties

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

By MedXY 08/17/2025

The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor identification.